MedTrace Logo

This Study is a Prospective, Multi-center, Real World, Observational Study, Which Aims at Evaluating Intermediate and Long-term Efficacy of Endovascular Treatment for TASC C&D Aortoiliac Occlusive Disease.

NCT05391815 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 800

Last updated 2022-05-26

No results posted yet for this study

Summary

This study is a prospective, multi-center, real world, observational study, which aims at evaluating the intermediate and long-term efficacy of endovascular treatment for TASC C\&D aortoiliac occlusive disease .It is estimated that 800 subjects diagnosed with TASC C\&D aortoiliac occlusive disease and receive endovascular treatments will be enrolled in nine centers from April 2021 to June 2027 nation-widely. All the subjects will be under follow-up for 60 months. There is no restriction on the endovascular techniques. The primary outcomes covers freedom from TLR at 60 months.

Conditions

  • Peripheral Arterial Disease

Sponsors & Collaborators

  • RenJi Hospital

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Chengdu University of Traditional Chinese Medicine

    collaborator OTHER

  • Xuanwu Hospital, Beijing

    collaborator OTHER

  • First People's Hospital of Hangzhou

    collaborator OTHER

  • Qingdao Hiser Medical Group

    collaborator OTHER

  • Second Affiliated Hospital of Soochow University

    collaborator OTHER

  • Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology

    collaborator UNKNOWN

  • Huashan Hospital

    collaborator OTHER

  • Shanghai Zhongshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2027-06-01
Completion
2032-06-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05391815 on ClinicalTrials.gov